CorMedix reported positive adjusted EBITDA and increased its full-year 2025 pro forma net revenue guidance. The company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL, providing diversified revenue streams beyond its lead product.
Cyborg Score Rationale
The company achieved positive adjusted EBITDA and increased 2025 pro forma guidance, indicating operational progress post-DefenCath launch. However, operating income of -$22.4M on a trailing twelve-month basis and short interest of 23.0% of float with 112% increase over 12 months signal execution and investor sentiment risks.
Top Insights
FDA approval of DefenCath in November 2023 stands as the most transformative event in CorMedix's history, validating years of research and fundamentally changing the company's valuation proposition.
The shift following FDA approval required significant operational transformation throughout 2024, building commercial infrastructure, establishing supply chains, negotiating with payors, and initiating sales efforts.
Significant goodwill and intangible assets are associated with the Melinta acquisition, indicating material balance sheet impact from portfolio expansion.
Current ratio of 3.39 indicates the company's ability to pay short-term obligations.
Named Competitors
Vancomycin and other conventional antibiotic lock solutions — Traditional antibiotic approaches to CRBSI prevention
Chlorhexidine/heparin lock solutions — Alternative catheter lock technologies
Recent Developments
(January 2026) CEO Joseph Todisco assumed Chairman role; Mike Seckler appointed as Executive Vice President and Chief Operating Officer
(November 2025) Reported Q3 2025 results with positive adjusted EBITDA and increased full-year 2025 pro forma revenue guidance
(2025) Continued DefenCath commercialization and Melinta portfolio integration driving revenue growth
Open the full interactive CorMedix Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.